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Coincidence of bft and cfiA genes in a multi-resistant clinical
isolate of Bacteroides fragilis
Although a common member of the
normal human gut flora, Bacteroides
fragilis possesses various virulence factors,
such as capsule, LPS and special surface
proteins, and certain types of strains may
produce an extracellular enterotoxin,
termed fragilysin (BFT). The fragilysin-
encoding gene (bft) has three different
isoforms (termed bft-1, bft-2 and bft-3)
(Chung et al., 1999; Franco et al., 1997;
Kling et al., 1997). Because of the increasing
number of resistant B. fragilis isolates, the
therapeutic possibilities have been restricted
to only some antibiotics, such as
piperacillin/tazobactam, imipenem,
metronidazole, clindamycin and cefoxitin
(Rasmussen et al., 1993). Out of these,
metronidazole and imipenem are the drugs
of choice in the treatment of infections
caused by B. fragilis; however, the emergence
of imipenem or metronidazole resistant
isolates has been reported (Rasmussen et al.,
1993). Carbapenem and metronidazole
resistances are frequently associated with the
presence of the cfiA gene encoded class B
metallo-b-lactamase (Thompson &
Malamy, 1990) or various types of
5-nitroimidazole resistance genes (nimA–G)
(Gal & Brazier, 2004). Strains carrying the
cfiA gene may show susceptibility to
imipenem, because in most isolates this
gene is silent, but the presence of insertion
(IS) elements in the upstream region of this
gene can lead to the development of
carbapenem resistance (Podglajen et al.,
1992).
By using various molecular typing
methods, such as arbitrarily primed-PCR,
PFGE and multilocus enzyme
electrophoresis, bft-positive, cfiA-negative
strains and bft-negative, cfiA-positive
strains belonged to two different DNA
homology groups, and the coexistence of
bft and cfiA genes was not detected
(Gutacker et al., 2000; Vallim et al., 2002).
During examination of the prevalence of
bft- or cfiA-positive B. fragilis strains
isolated from various clinical specimens,
we found a multi-resistant B. fragilis strain
R19811 isolated from a blood culture and
identified by rDNA RFLPs in the Anaerobe
Reference Laboratory, Cardiff (Wareham
et al., 2005). This strain co-harboured the
cfiA and bft genes; therefore, our aim was
to characterize its genetic background.
B. fragilis strain R19811 and control strains
were cultured as previously described
(So´ki et al., 2000). The list and the
description of the control strains have been
described before (So´ki et al., 2006).
MICs to a range of antibiotics were
determined by using the E-test method
(AB Biodisk) according to the
manufacturer’s instructions. B. fragilis
strain R19811 was multi-resistant to
penicillin G (MIC ¢256 mg ml21),
amoxicillin/clavulanic acid (MIC¢256 mg
ml21), cefoxitin (MIC ¢256 mg ml21),
imipenem (MIC ¢256 mg ml21),
clindamycin (MIC ¢256 mg ml21) and
metronidazole (MIC564 mg ml21).
Because of the imipenem resistance, the
presence of cfiA gene encoding metallo-b-
lactamase was tested. cfiA PCR (Podglajen
et al., 1992; Thompson & Malamy, 1990)
revealed that the strain carried the cfiA
gene, at the same time the presence of bft
gene was also detected by PCR according
to Pantosti et al. (1997).
We analysed the upstream region of the
cfiA gene to detect IS elements,
hypothesizing that the occurrence of one
of these sequences may contribute to the
development of carbapenem resistance
mechanisms; in B. fragilis strain R19811 an
insertion was detected in the upstream
region of cfiA gene by G and Up2 primers,
as described by Podglajen et al. (1994).
To determine the type of this element,
various primers, IS614 (IS614-1i,
59-GAAATTGTGTATCAATGCCG-39 and
IS614-2i, 59-CTGATACCATCCTCAGAG-
CC-39), IS942 (Rasmussen & Kovacs,
1991), IS1169 (Trinh et al., 1995), IS1170/1
and IS1170/2 (Trinh et al., 1995), IS1186
(Podglajen et al., 1994), and IS4351
(Podglajen et al., 1994; Rasmussen et al.,
1987) were tested for use in PCR. During
these amplification reactions, standard
PCR reaction mixture was used, as
described previously by So´ki et al. (2006).
Of the examined IS elements, only IS614
was detected by PCR. Partial nucleotide
sequence data of the upstream region of
the cfiA gene by Up2, G, IS614-1i and
IS614-2i primers, as described by So´ki et al.
(2004), confirmed that it is an IS614B
element.
B. fragilis strain R19811 contained
plasmids with an estimated molecular
mass of 5.6 and 9.9 kb using HindIII
restriction enzyme (Pharmacia Biotech)
analysis. In spite of the fact that cfiA
gene could be on a plasmid (Bandoh et al.,
1992; Nakano et al., 2004), in our case,
Southern blot hybridization, showed it
was not.
In spite of the observed metronidazole
resistance, nim genes commonly
responsible for metronidazole resistance in
the B. fragilis group could not be detected
using the nim-3 and nim-5 primer pair
(Trinh & Reysset, 1996), which is suitable
for the detection for all described nim
genes. The annealing temperature of nim
PCR was reduced from 62 to 52 uC to
show incidental sequence variation in the
nim gene, but PCR products could not be
detected. Further investigations are
necessary to establish the metronidazole
resistance mechanism in this organism.
In numerous earlier studies, the presence
of the cfiA gene was never observed
together with the cepA gene encoding
endogenous class A b-lactamase, because
cfiA-positive and cepA-positive strains
belong to two genetically distinct groups.
The first group was characterized by the
presence of cfiA gene, while in the second
group, the presence of the cepA gene is
typical with or without the presence of the
bft gene. In spite of this observation, in
2005, Ayala et al. (2005) described two
B. fragilis strains (7160 and 213E), which
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possess both the cepA and the cfiA gene.
In strain R19811, no amplification product
was detected with cepA PCR as described
by Gutacker et al. (2000). This suggests
that the strain originally belonged to the
cfiA-positive group.
In the cytotoxicity assay, as described by
Pantosti et al. (1994), B. fragilis strain
R19811 caused a reversible cytopathic
effect on the HT-29 cell line, this result
indicated that in the cell culture
supernatant, functional toxin, namely
fragilysin was present. PCR-RFLP
analysis of the bft gene by BTT1
(59-CATGTTCTAATGAAGCTGATTC-39)
and BTT2 (59-ATCGCCATCTGCTGTTT-
CCC-39) primers, with minor modification
according to Chung et al. (1999),
revealed a bft-1 allele.
To clarify the epidemiological background
of this strain, enterobacterial repetitive
intergenic consensus (ERIC) PCR typing
(Versalovic et al., 1991) was applied in
the case of bft-positive and cfiA-negative,
bft-negative and cfiA-positive, bft- and
cfiA-negative strains, and the PCR patterns
were compared with the result of ERIC
PCR in B. fragilis strain R19811. Two
homology groups of B. fragilis can be
distinguished by using molecular typing
methods as described previously by
Gutacker et al. (2000), Moraes et al. (1999)
and Ruimy et al. (1996): the first group is
characterized by the presence of the cfiA
gene, these strains were bft-negative, while
the strains in the second group carried
only the bft gene (Fig. 1). ERIC PCR typing
suggested that strain R19811, which
harboured the bft and cfiA gene
simultaneously, may be related to the first
group, which contained only cfiA-positive
strains (Fig. 1).
In summary, analysis of the results of
cfiA and cepA PCR, and ERIC typing
pattern, indicated that B. fragilis strain
19811 originally carried the cfiA gene and
acquired the bft gene only later. Franco
(2004) described two new related
conjugative transposons (CTn86 and
CTn9343) in connection with the bft
gene. Recently, a more divergent picture
has arisen. The two conjugative
transposons differ in two regions: one,
BfPAI, found exclusively on CTn86 and
harbouring the bft genes, and the other
exclusively harbouring an additional 7 kb
region and found on CTn9343. However,
these two additional regions with the left-
end of the transposons may result in
hybrid elements. Still, the presence of
CTn86 is mainly characteristic for bft
genes and the pattern I of B. fragilis
strains, while CTn9343 and the CTn9343-
like elements mainly result in pattern III.
The cfiA gene, however, was found only
in pattern II and some pattern III
isolates, but still in division II (Buckwold
et al., 2007). If genes responsible for the
transfer of these CTns are functional, it is
possible that the bft gene can be
transferred from an enterotoxigenic strain
to a nontoxigenic strain. The presence of
new transmissible CTns, and virulence
and resistance genes, may contribute to
the enhancement of the pathogenicity
potential and the fitness of this strain;
therefore, the aforementioned factors may
promote the development of more severe
infection, which may be unresponsive to
the majority of the therapeutic
possibilities.
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Fig. 1. Comparative ERIC1-2 PCR pattern of B. fragilis strain R19811. Two groups of B. fragilis strains with similar patterns
are indicated: the cfiA- and bft-positive strain R19811 in triplicate (first group) and bft-negative, cfiA-positive strains (second
group). Lanes 1–3, cfiA- and bft-positive B. fragilis strain R19811; lanes 4–6, bft-positive and cfiA-negative isolates; lanes
7–9, bft-negative strains and cfiA-positive strains; lanes 10–11, bft-negative and cfiA-negative B. fragilis strains; lane 12,
Bacteroides thetaiotaomicron; lane 13, ‘Bacteroides variabilis’. M, 100 bp ladder (Sigma; 100–1000 bp).
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